`
`http://www.ncbi.nlm.nih.gov/pubmed/17979030
`
`Abstract
`
`Curr Opin Investig Drugs. 2007 Nov;8(11):955-62.
`Drug evaluation: BG-12, an immunomodulatory dimethylfumarate.
`1
`Wakkee M , Thio HB.
`Author information
`
`Abstract
`Biogen Idec Inc, following its acquisition of Fumapharm AG, is developing BG-12 (Panaclar, BG-00012,
`FAG-201), an oral second-generation fumarate derivative, for the potential treatment of multiple sclerosis
`(MS). In January 2007, a phase III program for relapsing-remitting MS patients was initiated. The company
`was also developing the drug for psoriasis and, in October 2003, Biogen Idec expected to commence phase
`III trials for psoriasis in the US in the following year. In April 2005, the drug met its European phase III
`psoriasis trial endpoint, with the data expected to be used to support a market authorization filing in Germany
`in 2005. It was later disclosed that while an application had been filed, this was subsequently withdrawn
`based on a joint decision by Fumapharm and Biogen Idec. No further development has been reported on
`BG-12 for psoriasis in the US and it was not listed as a pursued indication on Biogen Idec's April 2007
`pipeline.
`
`PMID: 17979030 [PubMed - indexed for MEDLINE]
`
`Publication Types, MeSH Terms, Substances
`
`LinkOut - more resources
`
`PubMed Commons
`
`0 comments
`
`PubMed Commons home
`
`How to join PubMed Commons
`
`1 of 1
`
`4/16/2015 1:18 PM
`
`Page 1 of 1
`
`